| Literature DB >> 35821743 |
Joanna Saleh1, Wasim S El Nekidy1, Rania El Lababidi1.
Abstract
Background: There is a gap in antimicrobial stewardship in transitions of care.Entities:
Year: 2022 PMID: 35821743 PMCID: PMC9271486 DOI: 10.1093/jacamr/dlac065
Source DB: PubMed Journal: JAC Antimicrob Resist ISSN: 2632-1823
Definitions of endpoints
| Endpoint | Definition |
|---|---|
| CDI | Infection with |
| MDR | Multidrug-resistant organisms, defined as pathogens not susceptible to at least one antibiotic in at least three classes to which the pathogen is generally expected to be susceptible. |
| Appropriate antibiotics | Prescribed regimen with the right antimicrobial agent, the right dose, for the right duration, and ability to meet diagnostic criteria. This is as per our institutional Antimicrobial Use Guidelines, IDSA guidelines, and as per the patient’s allergies and cultures and patient’s previous bacterial colonization history. |
| Re-admission | Re-admission to the hospital due to an infection within 30 days of previous infection in the same site. |
| Recurrence | Infection with the same bacteria within 14 days of discharge. |
| Relapse | Infection in the same site with a different bacterium within 30 days of discharge. |
| Resistance | Development of infection with bacteria resistant to 3 or more antibacterial drug classes within 30 days of antibiotic administration. |
Demographics and baseline characteristic of the study sample
| Variable | All ( | Overall appropriate ( | Overall inappropriate ( |
|
|---|---|---|---|---|
| Gender (female), | 68 (46.9) | 21 (47.7) | 47 (46.5) | 0.895 |
| Age, years, median (IQR) ( | 56 (34.5–73) | 57.5 (39.25–73.5) | 56 (32.25–73) | 0.484 |
| Diabetes, | 81 (55.9) | 22(50) | 42 (41.6) | 0.348 |
| Hypertension, | 25 (34.2) | 25 (56.8) | 48 (47.5) | 0.303 |
| Chronic kidney disease, | 30 (20.7) | 11 (25) | 19 (18.8) | 0.398 |
| Liver disease, | 2 (1.4) | 1 (2.3) | 1 (1) | 0.516 |
| Chronic artery disease, | 34 (23.8) | 12 (27.9) | 22 (21.7) | 0.447 |
| History of MDRO, | 5 (3.4) | 1 (2.3) | 4 (4) | 0.520 |
| Primary infection, | 0.843 | |||
| UTI | 52 (35.9) | 16 (36.4) | 36 (35.6) | |
| PNA | 30 (20.7) | 9 (20.5) | 21 (20.8) | |
| IAI | 31 (21.4) | 11 (25) | 20 (19.8) | |
| SSTI | 32 (22.1) | 8 (18.2) | 23 (23.8) | |
| Route at discharge (oral), | 128 (97.7) | 37 (94.9) | 91 (98.9) | 0.211 |
MDRO, multidrug-resistant organism; UTI, urinary tract infection; PNA, pneumonia; IAI, intrabdominal infections; SSTI, skin and soft tissue infection.
Treatment outcomes
| Variable | All ( | Appropriate ( | Inappropriate ( |
|
|---|---|---|---|---|
| Appropriate antimicrobial | 119 (82.1) | 44 (100) | 75 (74.3) | <0.001 |
| Appropriate dose | 139 (95.9) | 44 (100) | 95 (94.1) | 0.109 |
| Appropriate duration | 61 (42.1) | 44 (100) | 17 (16.8) | <0.001 |
| Failure to meet diagnostic criteria | 18 (12.4) | 0 (0) | 18 (17.8) | 0.003 |
| Readmission within 30 days | 11 (7.6) | 3 (6.8) | 8 (7.9) | 0.559 |
| Recurrence within 14 days | 5 (3.4) | 1 (2.3) | 4 (4) | 0.520 |
| Relapse within 30 days | 6 (4.1) | 2 (4.5) | 4 (4) | 0.591 |
| Resistance development | 1 (0.7) | 1 (1.6) | 0 (0) | 0.299 |
| CDI within 30 days | 1 (0.7) | 0 (0) | 1 (1) | 0.697 |
All values shown are n (%). CDI, C. difficile infection.